LivaNova PLC has made a significant filing with the U.S. Securities and Exchange Commission (SEC) on November 4, 2026, related to compliance with the Iran Threat Reduction and Syria Human Rights Act of 2012. This filing, categorized as an IRANNOTICE, indicates the company's adherence to disclosure requirements concerning its business activities in relation to Iran.

The filing is important as it underscores LivaNova's commitment to regulatory compliance in the electromedical and electrotherapeutic apparatus industry. It reflects the ongoing scrutiny that companies face regarding their international operations, particularly in regions subject to sanctions and human rights concerns.

Background

LivaNova PLC, incorporated in the United Kingdom, operates in the electromedical and electrotherapeutic apparatus sector, as classified under the Standard Industrial Classification (SIC) code 3845. The company is publicly traded on the Nasdaq under the ticker symbol LIVN. LivaNova has a history of innovation in medical devices, focusing on improving patient outcomes through advanced technology.

What the Filing Says

The IRANNOTICE states, "Pursuant to Section 219 of the Iran Threat Reduction and Syria Human Rights Act of 2012 and Section 13(r) of the Securities Exchange Act of 1934, as amended, notice is hereby provided that LivaNova PLC has made disclosure pursuant to those provisions in its Quarterly Report on Form 10-Q for the period ended September 30, 2026, which was filed with the Securities and Exchange Commission on November 4, 2026." This statement highlights the company's proactive approach to transparency regarding its operations.

Impact

This filing may affect various stakeholders, including shareholders, regulatory bodies, and the broader medical device industry. By adhering to these disclosure requirements, LivaNova aims to maintain trust with investors and regulators while navigating complex international regulations.

What's Next

The filing does not say what happens next. However, it is likely that LivaNova will continue to monitor its compliance with relevant regulations and may provide further updates in future filings.